Marc Carrier on the WAVe Study: Weight-Adjusted Dalteparin is Safe & Effective in Large Cancer Patients with VTE
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on X:
“New in American Journal of Hematology – The WAVe Study
In patients >90 kg with cancer-associated VTE, weight-adjusted dalteparin (up to 33,000 IU/day) showed acceptable 30-Day bleeding (5.3%) and low recurrence (1.2%), supporting individualized dosing.”
Title: A Multicenter Prospective Cohort Study on the Use of Weight-Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism—The WAVe Study
Authors: Tzu-Fei Wang, Erik Yeo, Peter L. Gross, Chantal Séguin, Cynthia Wu, Sudeep Shivakumar, Ranjeeta Mallick, Aurélien Delluc, Julien D’Astous, Miriam Kimpton, Guillaume Roberge, Deborah M. Siegal, Tobias Tritschler, Grégoire Le Gal, Marc Carrier
Read full article here.
Stay updated with Hemostasis Today.
-
Jun 10, 2026, 18:22Winai Porntipworawech: The $50 Life-Saving Drug Big Pharma Doesn’t Want You to See
-
Jun 10, 2026, 18:09Leonard Valentino: Innovation in Blood Disorders Being Catalyzed by Pathway to Cures
-
Jun 10, 2026, 18:00Smitirupa Mishra: Normal Hemoglobin Does Not Always Mean Normal Genes
-
Jun 10, 2026, 17:58Talat Uppal: Addressing HMB with RACGP’s Dr. Ramya Raman
-
Jun 10, 2026, 17:52Throw Back Thursday to Past Bruises Posted in the Glanzmann’s Research Foundation
-
Jun 10, 2026, 17:52Priya Prasad: In Massive Hemorrhage, Fibrinogen Is Often the First Clotting Factor to Fall
-
Jun 10, 2026, 17:51Mariam Swidan: Some Red Blood Cells Can’t Handle Pressure
-
Jun 10, 2026, 17:49Ankit Mathur: Hosting ISBT Academy Day on Rare Donor Program in India
-
Jun 10, 2026, 17:48Shadi Tabibian: When Patients Bleed but Standard Testing Is Normal